Can I read Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001 on EtoBox?

Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001 by Vinai Gondi; Snehal Deshmukh; Paul D. Brown; Jeffrey S. Wefel; Terri S. Armstrong; Wolfgang A. Tome; Mark R. Gilbert; Andre Konski; Clifford G. Robinson; Joseph A. Bovi; Tammie L.S. Benzinger; David Roberge; Vijayananda Kundapur; Isaac Kaufman; Sunjay Shah; Kenneth Y. Usuki; Andrew M. Baschnagel; Minesh P. Mehta; Lisa A. Kachnic is a Medicine article available to read on EtoBox.

What is Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001 about?

Purpose: Initial report of NRG Oncology CC001, a phase 3 trial of whole-brain radiation therapy plus memantine (WBRT + memantine) with or without hippocampal avoidance (HA), demonstrated neuroprotective effects of HA with a median follow-up of fewer than 8 months. Herein, we report the final results with complete cognition, patient-reported outcomes, and longer-term follow-up exceeding 1 year. Methods and Materials: Adult patients with brain metastases were randomized to HA-WBRT + memantine or WBRT + memantine. The primary endpoint was time to cognitive function failure, defined as decline using the reliable change index on the Hopkins Verbal Learning Test-Revised (HVLT-R), Controlled Oral Word Association, or the Trail Making Tests (TMT) A and B. Patient-reported symptom burden was assessed using the MD Anderson Symptom Inventory with Brain Tumor Module and EQ-5D-5L. Results: Between July 2015 and March 2018, 518 patients were randomized. The median follow-up for living patients was 12.1 months. The addition of HA to WBRT + memantine prevented cognitive failure (adjusted hazard ratio, 0.74, P = .016) and was associated with less deterioration in TMT-B at 4 months (P = .012) and HV

Who reads Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001?

Author

Vinai Gondi; Snehal Deshmukh; Paul D. Brown; Jeffrey S. Wefel; Terri S. Armstrong; Wolfgang A. Tome; Mark R. Gilbert; Andre Konski; Clifford G. Robinson; Joseph A. Bovi; Tammie L.S. Benzinger; David Roberge; Vijayananda Kundapur; Isaac Kaufman; Sunjay Shah; Kenneth Y. Usuki; Andrew M. Baschnagel; Minesh P. Mehta; Lisa A. Kachnic

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)